Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 3 9Phase 1/2 2Phase 1 2Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Oxaliplatin 11Docetaxel 8Fluorouracil 6Capecitabine 6Trastuzumab 5Leucovorin 5Drug Therapy 5apatinib 4S 1 (combination) 4Tegafur 3Paclitaxel 3Nivolumab 3Irinotecan 3Cisplatin 3sintilimab 2disitamab vedotin 2Surgical Procedures, Operative 2Standard of Care 2Ramucirumab 2Hyperthermic Intraperitoneal Chemotherapy 2Epirubicin 2vinflunine 1toripalimab 1titanium silicide 1tislelizumab 1taxane 1polysaccharide-K 1pertuzumab 1margetuximab 1gimeracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Stomach Neoplasms × titanium silicide × Clear all
NCT00639327 2011-06-28

Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer

Japan Clinical Cancer Research Organization

Phase 2/3 Completed
300 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡